依那西普长期治疗早期非放射学中轴型脊柱关节炎的104周随机对照研究
该研究评估依那西普对早期活动性非放射学中轴型脊柱关节炎患者的长期临床和影像学疗效。患者先接受12周双盲依那西普50mg/周或安慰剂,随后开放标签依那西普至104周。结果显示临床和MRI炎症指标持续改善,安全性与已知一致。
要点
- 104周时,持续依那西普组ASAS20应答率为75%,ASAS40为61%。
- ASDAS非活动性疾病达60%,BASDAI50应答达70%。
- 临床和MRI SPARCC评分从基线至104周持续改善,无新安全信号。
核心结论
- 对至少2种NSAIDs反应不足的早期活动性非放射学中轴型SpA患者,依那西普治疗104周可维持临床和影像学改善。
研究设计与样本
- 随机、双盲、安慰剂对照研究,12周双盲期后开放标签依那西普50mg/周至104周。
- 纳入215例符合ASAS分类标准但不符合改良纽约放射学标准的成人患者,症状持续>3个月至<5年。
主要发现
- 104周时,持续依那西普组ASAS20、ASAS40、ASDAS非活动性疾病和BASDAI50应答率分别为75%、61%、60%和70%(观察值)。
- 从基线至104周,持续依那西普组和安慰剂转依那西普组的ASDAS-CRP分别下降1.5和1.7,BASDAI分别下降3.3和3.8(LOCF)。
- SPARCC MRI骶髂关节评分分别下降6.0和3.4,脊柱评分分别下降2.1和0.8(观察值)。
- 严重不良事件发生率在持续依那西普组为8%,安慰剂转依那西普组为7%,未见新安全信号。
临床怎么用
- 对于NSAIDs反应不足的早期非放射学中轴型SpA,可考虑依那西普长期治疗以持续改善临床和影像学炎症。
局限性
- 12周后为开放标签设计,缺乏长期安慰剂对照。
- 部分数据采用LOCF或观察值分析,可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the long-term clinical and imaging efficacy of etanercept in patients with early, active nonradiographic axial spondyloarthritis (SpA). METHODS: Adult patients who satisfied the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial SpA (but not the modified New York radiographic criteria), with symptom duration >3 months to <5 years, and who were unresponsive to ≥2 nonsteroidal antirheumatic drugs (NSAIDs) received double-blind etanercept 50 mg/week or placebo for 12 weeks, followed by open-label etanercept 50 mg/week to week 104. Clinical, magnetic resonance imaging (MRI; Spondyloarthritis Research Consortium of Canada [SPARCC] scores), and safety outcomes at 104 weeks were analyzed. RESULTS: Of 215 randomized patients (etanercept: n = 106; placebo: n = 109), 205 entered the study (etanercept/etanercept: n = 100; placebo/etanercept: n = 105) and 169 completed the open-label period (etanercept/etanercept: n = 83; placebo/etanercept: n = 86). At week 104, 61 of 81 (75%), 49 of 81 (61%), 48 of 80 (60%), and 57 of 81 (70%) patients who received etanercept throughout the trial achieved ASAS20, ASAS40, Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease, and Bath Ankylosing Spondylitis Disease Activity Index criteria for 50% improvement (BASDAI 50) scores, respectively (observed). From baseline to week 104, continued improvements in clinical outcomes (ASDAS-C-reactive protein: -1.5 and -1.7; BASDAI: -3.3 and -3.8 [last observation carried forward]), and SPARCC MRI scores (sacroiliac joint: -6.0 and -3.4; spinal: -2.1 and -0.8 [observed]) were seen in patients receiving etanercept/etanercept and placebo/etanercept. During the study, 8% in the etanercept/etanercept group and 7% in the placebo/etanercept group had serious adverse events; no new safety signals were seen. CONCLUSION: Patients with early, active nonradiographic axial SpA and an inadequate response to at least 2 NSAIDs demonstrated improvement in clinical and imaging outcomes that were sustained through 104 weeks of etanercept treatment.
引用
- Dougados M, van der Heijde D, Sieper J, et al. Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study. Arthritis Care Res (Hoboken). 2017. PMID: 28482137. doi:10.1002/acr.23276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。